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Patients with severe stroke due to acute large cerebral artery occlusion are likely to be se-
verely disabled or dead without timely reperfusion. Previously, intravenous tissue plasmino-
gen activator (IV-TPA) within 4.5 hours after stroke onset was the only proven therapy, but 
IV-TPA alone does not sufficiently improve the outcome of patients with acute large artery 
occlusion. With the introduction of the advanced endovascular therapy, which enables more 
fast and more successful recanalization, recent randomized trials consecutively and consis-
tently demonstrated the benefit of endovascular recanalization therapy (ERT) when added 
to IV-TPA. Accordingly, to update the recommendations, we assembled members of the 
writing committee appointed by the Korean Stroke Society, the Korean Society of Interven-
tional Neuroradiology, and the Society of Korean Endovascular Neurosurgeons. Reviewing 
the evidences that have been accumulated, the writing members revised recommendations, 
for which formal consensus was achieved by convening a panel composed of 34 experts 
from the participating academic societies. The current guideline provides the evidence-
based recommendations for ERT in patients with acute large cerebral artery occlusion re-
garding patient selection, treatment modalities, neuroimaging evaluation, and system orga-
nization. 
Keywords Guidelines; Acute ischemic stroke; Large cerebral artery occlusion; Thrombolysis; 
Reperfusion; Endovascular recanalization therapy
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Introduction
Previously, intravenous tissue plasminogen activator (IV-
TPA) within 4.5 hours after stroke onset was the only therapy 
with proven efficacy from randomized clinical trials (RCTs) 
for acute ischemic stroke.1-3 However, patients with severe 
stroke due to acute large cerebral artery occlusion are less re-
sponsive to IV-TPA alone and are likely to be severely disabled 
or dead. For these patients, endovascular recanalization thera-
py (ERT) has been expected to achieve better recanalization 
and better outcome. A single RCT and a meta-analysis showed 
that ERT compared to no thrombolytic therapy increased re-
canalization rate and improved clinical outcomes.4,5 Despite 
an increased risk of symptomatic intracranial hemorrhage 
(SICH) with ERT, it was not translated to an increased mor-
tality.5 In contrast, when compared to IV-TPA, 3 RCTs pub-
lished in 2013 failed to show the benefit of ERT.6-8 These trials 
had major limitations of 1) the failure to confirm large artery 
occlusions in all patients before randomization and 2) the use 
of old endovascular technologies with insufficient and delayed 
recanalization. With the introduction of stent-retriever throm-
bectomy devices, multiple RCTs were simultaneously or con-
secutively initiated between December 2010 and February 
2013, and their final results were published between Decem-
ber 2014 and April 2015.9-13 All the trials consistently and con-
vincingly demonstrated the benefit of ERT added to IV-TPA 
in patients with severe stroke due to acute large cerebral artery 
occlusion. The successes of the 5 RCTs are likely attributed to 
1) right devices with better and faster recanalization, 2) right 
patient selection with appropriate vascular imaging, and 3) 
right system enabling to provide an expedited and organized 
care for ERT. Accordingly, the guideline writing committee 
decided to revise the Korean Clinical Practice Guidelines for 
Stroke to inform physicians of the new evidences from RCTs 
and to help incorporate the ERT into clinical practice by im-
plementing of stroke care system. 
Previous guidelines
The 2012 Korean Clinical Practice Guidelines for intra-ar-
terial (IA) thrombolysis in patients with acute ischemic stroke 
provided the following recommendations.3
 1. Intra-arterial thrombolysis can be considered for patients 
who have occlusions in the middle cerebral artery or the inter-
nal carotid artery of ≤ 6 hours, or those who are contraindicated 
for intravenous thrombolysis (for example, recent surgery) 
(Level of Evidence Ia, Grade of Recommendation A). – Revi-
sions made in the LOE and GOR.
2. The institution conducting IA thrombolysis should ac-
commodate a rapid access to cerebral angiography and experi-
enced interventionalists. Each institution is encouraged to de-
fine criteria of interventionalists who can perform IA throm-
bolysis (good practice points [GPP]). – Revisions made in 
the LOE and GOR.
3. IA thrombolysis can be considered for patients who have 
occlusions in the posterior circulation such as the basilar ar-
tery, depending on the criteria of each institution (LOE III, 
GOR B). – Revisions made in the LOE and GOR.
4. In patients indicated for IV-TPA, IV-TPA should be ad-
ministered first. For patients who have not responded to IV-
TPA, additional IA thrombolysis can be considered (LOE III, 
GOR B). – New recommendation.
5. Mechanical thrombectomy can be considered for patients 
presenting < 8 hours with major ischemic strokes caused by 
large artery occlusions. Stent retrievers are preferred to other 
devices, but the selection of treatment method should be made 
by responsible interventionalists, taking into account of the pa-
tient’s conditions (LOE Ib, GOR A). – New recommendation.
Methodology
Organization of the writing committee
The Clinical Practice Guideline Committee of the Korean 
Stroke Society assembled the writing members appointed by 
the Korean Stroke Society, the Korean Society of Interven-
tional Neuroradiology, and the Society of Korean Endovascu-
lar Neurosurgeons. 
Evidence search and data analysis
To review and summarize the effect of ERT in acute isch-
emic stroke, we conducted a systematic review. We searched 
Pubmed and EMBASE ( January 1998 to May 2015) with the 
terms of ischemic stroke and intra-arterial and thrombolysis or 
thrombectomy with restriction to humans and clinical trials. 
Additional relevant articles were identified from manual 
searches of bibliographies of all trials and were solicited from 
the writing members. Two investigators (Ko SB and Hong 
KS) reviewed and selected eligible studies. The selection crite-
ria for the systematic review were 1) RCT, 2) ERT in the ac-
tive arm, 3) the control arm receiving standard therapy includ-
ing IV-TPA, but not treated with ERT, and 4) modified Rankin 
Scale (mRS) score reported at 90 days or at the end of the trial. 
From the literature review, we identified 15 relevant RCTs that 
tested ERT and reported mRS outcome in 2,899 patients: 
1,575 in the ERT group and 1,324 in the control group. Of the 
15 RCTs, 6 trials did not use IV-TPA in control arms (IV uro-
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kinase in one trial14),4,14-18 and 9 trials provided IV-TPA to 
29.6%8 to 100%6,11,12 of patients randomized to control arms.6-
13,19 In 5 RCTs, patients randomized to ERT were mainly treat-
ed with stent-retriever thrombectomy (77.1% to 95.1%).9-13 
We assessed and summarized the quality of each RCT using 
the Cochrane risk of-bias algorithm (www.cochrane.org/train-
ing/cochrane-handbook)20 and reported it in another article.21 
Data from eligible trials were independently abstracted by the 
two investigators (Ko SB and Hong KS), and discrepancies 
were resolved by consensus or discussion with other investiga-
tors (Yu KH and Rha JH). We estimated pooled effects of 
ERT for various clinical outcomes, and the detailed results 
were published elsewhere.21 
In addition, we searched updated guidelines or consensus 
statement for the organization of care system for ERT from 
credited academic societies, and identified 3 reports published 
since 2013.22-24 At the inception, we reviewed articles pub-
lished until May 2015. However, during the guideline writing 
after our literature search, an updated guideline of the Ameri-
can Stroke Association was released on 29 June 2015, which 
we additionally reviewed.25 All recommendations and state-
ments provided in the selected guidelines and statements were 
reviewed and reflected, if necessary, in the current guidelines.
LOE and GORs
We determined the LOE and the GOR for each recommen-
dation largely based on the suggestion of the US Agency for 
Healthcare Policy and Research (currently the Agency for 
Healthcare Research and Quality) in 1993 (Table 1).26 
Evidence summary
The characteristics and results of the 15 RCTs and their 
meta-analyses are summarized in Table 2.
Patient selection and ERT modality
Time window
The time window in the 15 RCTs ranged from 319 to 24 
hours17, and 8 RCTs randomized patients with 6 hours from 
onset.4,9,11,12,14-16,18 Of the recent 5 stent-retriever RCTs, the Mul-
ticenter Randomized Clinical trial of Endovascular treatment 
for Acute ischemic stroke in the Netherlands (MR CLEAN), 
Extending the Time for Thrombolysis in Emergency Neuro-
logical Deficits—Intra-Arterial (EXTEND-IA), and Solitaire 
with the Intention for Thrombectomy as Primary Endovascu-
lar Treatment (SWIFT PRIME) trials enrolled patients within 
6 hours from stroke onset.9,11,12 The Revascularization with 
Solitaire FR Device versus Best Medical Therapy in the Treat-
ment of Acute Stroke Due to Anterior Circulation Large Vessel 
Occlusion Presenting within Eight Hours of Symptom Onset 
(REVASCAT) and Endovascular Treatment for Small Core 
and Proximal Occlusion Ischemic Stroke (ESCAPE) trials en-
rolled patients up to 8 hours and 12 hours, but 90.3% of pa-
tients in REVASCAT and 84.5% of those in ESCAPE were en-
rolled within 6 hours.10,13 
In the 5 stent-retriever RCTs, on average, the groin puncture 
from onset was achieved within 4.5 hours (ranged in 185 min-
utes10 and 269 minutes13), and the first reperfusion was initiat-
ed within 6 hours (ranged in 241 minutes10 and 355 minutes13) 
from stroke onset. In particular, the ESCAPE and SWIFT 
PRIME trials emphasized the speed of workflow, which short-
ened the time from initial imaging to groin puncture of 51 
minutes and 57 minutes and from initial imaging to first reper-
fusion of 84 minutes and 81 minutes respectively.10,12
Infarct core, perfusion, and collaterals evaluation
Noncontrast CT is the most readily and widely available 
imaging modality to exclude hemorrhagic stroke and to iden-
tify patients with early extensive ischemic injury who would 
Table 1. Level of evidence (LOE) and grade of recommendation (GOR)
LOE
Ia Evidence obtained from meta-analysis of randomized controlled trials
Ib Evidence obtained from at least one randomized controlled trial
IIa Evidence obtained from at least one well-designed controlled study without randomization
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case 
   studies
IV Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities
GOR
   A (LOE Ia, Ib) Required - at least one randomized controlled trial as part of the body of literature of overall good quality and consistency addressing 
   specific recommendation
   B (LOE IIa, IIb, III) Required - availability of well conducted clinical studies but no randomized clinical trials on the topic of recommendation
   C (LOE IV) Required - evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. This grade 
   indicates absence clinical of directly applicable studies of good quality
Good practice points (GPP) Recommended best practice based on the clinical experience of the guideline development group
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be less responsive to and at high risk of SICH with ERT. Alber-
ta Stroke Program Early CT Score of 6-10 was defined as a 
small infarct core and one of the inclusion criteria in the ES-
CAPE, SWIFT PRIME (perfusion imaging at the inception 
and then modified to Alberta Stroke Program Early CT Score 
during the trial), and REVASCAT trials.10,12,13 MR CLEAN did 
not use Alberta Stroke Program Early CT Score for the patient 
selection, but only 5.6% of the enrolled patients had very low 
Alberta Stroke Program Early CT Score of 0-4.9 In contrast, 
EXTEND-IA used CT perfusion to select patients with a small 
ischemic core (area of cerebral blood flow less than 30% of nor-
mal tissue: < 70 mL on CT perfusion).11 The SWIFT PRIME 
trial also evaluated baseline perfusion imaging in 81% of the 
enrolled patients and selected patients with ischemic core less 
than 50 mL.12 
Patients with good collaterals are likely to have more salvage-
able tissue and to achieve good outcome with reperfusion. In 
addition, good collateral status was associated with a lower risk 
of SICH. The ESCAPE trial, using a collateral assessment with 
multiphase CT angiography (CTA), selected patients with 
moderate-to-good collaterals defined as > 50% filling of the 
middle cerebral artery territory.10 
Target vessel occlusion 
Now, CTA (MR angiography in some centers) is widely and 
immediately available in the emergent setting in most stroke 
centers. Patients with severe stroke are likely to have large cere-
bral artery occlusion. However, among patients with the Na-
tional Institute of Health Stroke Scale (NIHSS) score of 9 or 
more presenting within 3 hours, 19.3% had no major arterial 
occlusion.27 Of the 656 patients enrolled in the Interventional 
Management of Stroke (IMS) III trial, 306 (47%) underwent 
baseline CTA or MR angiography and a target vessel occlusion 
by vascular imaging was confirmed only in 282 (43%) before 
randomization. As a result, of the 434 patients assigned to 
ERT, 80 (18.4%) patients were judged by site investigators to 
have no thrombus deemed treatable by ERT.6 In an exploratory 
analysis of 220 patients with proximal artery occlusion con-
firmed by baseline CTA, ERT was associated with a higher re-
canalization rate at 24 hours and a favorable shift on the mRS 
score at 90 days.28 In contrast, all the 5 stent-retriever RCTs 
used CTA or MR angiography to select patients who had a tar-
get vessel occlusion in the intracranial carotid and/or middle 
cerebral artery. Of the patients enrolled in the 5 stent-retriever 
RCTs, 16.6%-31.4% had internal carotid artery occlusion, and 
54.3%-68.6% had M1 occlusion. Therefore, vascular imaging is 
strongly recommended in patients with severe stroke to assess 
large cerebral artery occlusions.
ERT modality
Prolyse in Acute Cerebral Thromboembolism (PROACT) 
II was the first phase 3 trial that assessed the effect of IA re-
combinant prourokinase.4 PROACT II did not allow mechani-
cal disruption. After then, the strategy to enhance recanaliza-
tion has evolved from mechanical disruption with micro-
guidewire through Merci embolectomy device and Penumbra 
aspiration to stent-retriever thrombectomy. In two phase 2 tri-
als comparing stent-retriever thrombectomy device (Solitaire 
Flow Restoration Device in one and Trevo Retriever in anoth-
er trial) with Merci device, the stent-retrievers had better re-
canalization rates, which were translated into improved clinical 
outcomes.29,30 In the Synthesis: A Randomized Controlled Tri-
al on Intra-Arterial Versus Intravenous Thrombolysis in Acute 
Ischemic Stroke (SYNTHESIS Expansion) trial that failed to 
show the superiority of ERT over IV-TPA, 66% of 165 patients 
receiving ERT were treated with IA TPA infusion plus me-
chanical disruption with a micro-guidewire and only 13.9% 
with Solitaire or Trevo device.7 The IMS III trial also used old 
endovascular technologies in most cases: IA infusion of TPA 
in 47.9%, Merci device in 28.4%, and Penumbra in 16.2%. 
Only 1.5% were treated with Solitaire stent-retriever. Of pa-
tients treated with ERT in IMS III, only 41% achieved good re-
canalization defined as modified Thrombolysis in Cerebral In-
farction 2b-3.6 In contrast, in the 5 stent-retriever trials, 58.7%9 
and 88.0%12 of patients assigned to ERT achieved recanaliza-
tion of modified Thrombolysis in Cerebral Infarction 2b-3.
Efficacy and safety of ERT
RCTs comparing ERT versus standard therapy since 1998
Overall, 15 RCTs involving 2,899 patients (1,575 in the ERT 
group and 1,324 in the control group) compared mRS outcome 
between the ERT and control groups (for control arms, no IV-
TPA in 6 trials4,14-18 and IV-TPA between 29.6% to 100% in 9 
trials6-13,19). In our updated meta-analysis,21 ERT was associated 
with increased mRS 0-2 outcome (pooled odds ratio [95% 
confidence interval], 1.79 [1.34, 2.40]; P < 0.0001; number 
needed-to-treat [NNT] = 9), mRS 0-1 outcome (1.81 [1.34, 
2.44]; P = 0.0001; NNT = 11), good neurological outcome 
(3.11 [2.14, 4.53]; P < 0.0001; NNT = 6), good activity of daily 
living (2.24 [1.78, 2.82]; P < 0.0001; NNT = 5), and partial or 
complete recanalization (4.50 [1.97, 10.27]; P = 0.0003; 
NNT = 3). The ERT and control groups did not differ in the 
rates of SICH (1.19 [0.83, 1.69]; P = 0.8695) and 90-day mor-
tality (0.87 [0.71, 1.05]; P = 0.1508; NNT = 55). However, 
ERT significantly reduced the extreme disability or death out-
come (mRS 5-6) (0.77 [0.61, 0.97]; P = 0.0246; NNT = 21).
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RCTs comparing stent-retriever thrombectomy versus 
standard IV-TPA
The 5 stent-retriever RCTs enrolled 1,278 patients: 633 in 
the ERT group and 645 in the control group. The median NI-
HSS score at baseline ranged from 13 to 18 in the control 
groups and from 16 to 17 in the ERT groups. IV-TPA was ad-
ministered in 77.0%13 to 100%11,12 in the control groups and 
68.0%13 to 100%11,12 in the ERT groups. The percentage of pa-
tients achieving good outcome defined by mRS 0-2 at 90 days 
ranged between 32.6%9 and 71.4%11 in the ERT groups and 
between 19.1%9 and 40%11 in the control groups. Across the 
trials, the absolute increase of mRS 0-2 outcome with ERT 
compared to standard therapy ranged between 13.5%9 and 
31.4%11, which was statistically highly significant. Therefore, 
the magnitude of benefit was substantial with an NNT for 
mRS 0-2 outcome between 3 and 7. ERT was significantly as-
sociated with a favorable shift on the mRS scores: the odds of 
improvement of 1 point on the mRS score, 1.679 to 3.110. 
SICH occurred in 0%11,12 to 7.7%9 in the ERT groups and 
1.9%13 to 6.4%9 in the control groups, and the absolute in-
crease in the SICH rate ranged between -5.7%11 and 1.3%9. In 
all trials, ERT did not significantly increase the risk of SICH. 
In the ESCAPE trial, 90-day mortality was significantly lower 
in the ERT group than in the control group,10 whereas, in the 
other 4 trials, 90-day mortality was non-significantly lower in 
the ERT groups than in the control groups.9,11-13 
When pooling data of the 5 stent-retriever RCTs,21 ERT was 
associated with increased mRS 0-2 outcome (pooled odds ra-
tio [95% confidence interval]; 2.39 [1.88, 3.04]; P < 0.0001; 
NNT = 5), mRS 0-1 outcome (2.49 [1.85, 3.36]; P < 0.0001; 
NNT = 7), good neurological outcome (3.62 [2.26, 5.78]; 
P < 0.0001; NNT = 4), good activity of daily living (2.53 [1.83, 
3.52]; P < 0.0001; NNT = 5), and partial or complete recanali-
zation (5.68 [3.09, 10.45]; P < 0.0001; NNT = 3). The SICH 
rate was comparable between the ERT and control groups 
(1.08 [0.61, 1.88]; P = 0.7983). Mortality reduction with ERT 
was not significant (0.78 [0.54, 1.12]; P = 0.1770; NNT = 29), 
but the extreme disability or death outcome (mRS 5-6) was 
significantly reduced with ERT (0.57 [0.41, 0.78]; P = 0.0006; 
NNT = 9).
ERT in patients with posterior circulation stroke
Patients with severe stroke due to large artery occlusion in 
the posterior circulation usually have severe disability and 
mortality without timely recanalization. However, the benefit 
of ERT in these patients has not been confirmed by large 
RCTs. In a small RCT including only 16 patients, good out-
come was achieved in 50% of patients treated with ERT and 
12.5% in the control group (P = 0.28).17 In another 3 RCTs, 
3.0%-19.3% of patients had posterior circulation strokes, but 
the result of subgroup analysis for posterior circulation was 
not reported or showed no benefit of ERT.6,7,19 The 5 stent-re-
triever RTCs exclusively enrolled patients with large artery 
occlusion in the anterior circulation. In a recent meta-analysis 
of 45 observational studies (41 ERT and 4 IV-TPA studies) 
involving 2,056 patients with acute basilar artery occlusion, 
ERT was associated with reduced death or dependency (0.67 
[0.61, 0.72]) and reduced mortality (0.48 [0.42, 0.55]).31
Other Issues
IV-TPA before ERT
IV-TPA within 4.5 hours of stroke onset is a proven therapy 
despite its limited efficacy in patients with acute large cerebral 
artery occlusion. In the 5-stent retriever RCTs, IV-TPA was 
given to most patients randomized to the ERT (68.0%13 to 
100%11,12) and control (77.0%13 to 100%11,12) arms. Since the 
SICH rates did not differ between the ERT and control groups, 
IV-TPA might account for the SICH in most patients. Howev-
er, IV-TPA before ERT could result in complete recanalization 
of proximal large cerebral artery occlusion in some patients, fa-
cilitate recanalization of proximal artery occlusion with ERT, 
and improve reperfusion in the distal branch. In the SYNTHE-
SIS Expansion trial that failed to show the superior efficacy of 
ERT over IV-TPA alone, patients assigned to ERT were not 
treated with IV-TPA.7 Therefore, there is no evidence to avoid 
IV-TPA in patients eligible for ERT. For patients treated with 
IV-TPA, REVASCAT selected patients with persistent arterial 
occlusion after 30 minutes of IV-TPA infusion,13 and MR 
CLEAN did not specifically report whether the investigators 
waited for clinical response to IV-TPA.9 In contrast, to start 
ERT as soon as possible, the ESCAPE, EXTEND-IA, and 
SWIFT PRIME trials proceeded ERT during IV-TPA adminis-
tration without waiting for clinical response to IV-TPA.10-12
Because both ERT and IV-TPA would increase the risk of 
SICH, some physicians might consider a low dose of IV-TPA 
for patients indicated for ERT. The IMS III trial employed a re-
duced IV-TPA dose of 0.6 mg/kg for patients in the ERT group 
at the inception. However, it was changed to the standard dose 
of 0.9 mg/kg after the protocol amendment during the trial.6 
All the 5 stent-retriever trials used the standard dose of IV-TPA 
for both the ERT and control groups.9-13 Accordingly, the cur-
rent evidence suggest that the standard IV-TPA dose of 0.9 
mg/kg would be reasonable in patients eligible for ERT.
Conscious sedation versus general anesthesia
Severe stroke patients indicated for ERT are usually poorly 
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cooperated and sometimes seriously agitated, which might in-
crease the risk of endovascular procedure complication. 
Therefore, several centers prefer general anesthesia over con-
scious sedation. However, general anesthesia likely delays 
treatment initiation, potentially results in hypotension that 
would worsen perfusion in penumbra, and precludes neuro-
logical monitoring. 
In a recent meta-analysis of 9 studies, general anesthesia 
was associated with increased risks of death (pooled odds ra-
tio [95% confidence interval], 2.59 [1.87, 3.58]) and respira-
tory complication (2.09 [1.36, 3.23]), and was associated 
with decreased odds of good functional outcome (0.43 [0.35, 
0.53]). Since patients on general anesthesia had more severe 
stroke, the results might be confounded by stroke severity.32 
However, in retrospective observational studies that adjusted 
covariates including NIHSS score, patients receiving general 
anesthesia had worse outcome.33-35 In the 5 stent-retriever tri-
als, 6.7%13 to 37.8%9 of patients in the ERT groups received 
general anesthesia. Currently, of the 5 stent-retriever RCTs, 
data on the effect of general anesthesia are available from MR 
CLEAN where 37.8% of patients in the ERT group received 
general anesthesia. In this post hoc analysis, patients on gen-
eral anesthesia had no benefit of ERT, and general anesthesia 
was associated with treatment delay.36 
System organization and quality improvement of ERT
ERT for acute ischemic stroke is the most complex and re-
source-intensive therapy that would not be available in all 
centers. Therefore, it would be reasonable to develop regional 
comprehensive stroke centers, which are closely connected to 
hospitals that are capable of IV-TPA treatment but incapable 
of ERT. It is generally recommended that centers providing 
ERT should implement an organized system of critical path-
way and a multidisciplinary team that is responsible for initial 
evaluation, decision making, and ERT procedure. 
Time is brain with ERT as well as with IV-TPA. A preplanned 
analysis of data from the IMS III trial showed that faster reper-
fusion was significantly associated with good outcome: 90-day 
good outcome of mRS 0-2 was achieved in 51.8% of patients 
with reperfusion within 5 hours, 45.4% in those within 5 to 6 
hours, and only 26.5% in those after 6 hours. Every 30-minute 
delay in reperfusion was associated with a 12% decreased likeli-
hood of achieving good outcome of mRS 0-2.37 In another 
study analyzing data of patients treated with Solitaire Flow Res-
toration stent-retriever, for every 15-minute acceleration of re-
perfusion, 31 per 1,000 treated patients had a favorable shift on 
the mRS score.38 Therefore, recent guidelines or consensus 
statements emphasize the expeditious assessment, decision, 
and initiation of ERT. The multisociety consensus quality im-
provement guidelines recommend door-to-neuroimaging eval-
uation within 25 minutes and door-to-neuroimaging interpre-
tation within 45 minutes in ≥ 80%, door-to-groin puncture 
within 120 minutes in ≥ 75%, and groin-puncture-to-first at-
tempt to recanalization within 45 minutes in ≥ 50% of ERT-
treated patients.23 Therefore, each center is encouraged to 
monitor and improve the time metrics. 
Since the RCTs testing ERT were generally conducted in 
experienced centers and selectively enrolled patients based on 
specific inclusion and exclusion criteria, the efficacy and safe-
ty findings from the RCTs might not be generalized to real 
world practice. Therefore, to further ensure the efficacy and 
safety of ERT in the setting of routine clinical practice, the 
data of clinical outcomes and complication need to be com-
plied at individual center level or more preferably at multi-
center registry level.
Consensus achievement
The writing members made a first draft including proposal 
of recommendations. To achieve consensus for the proposed 
recommendations using a modified Delphi method, we con-
vened a panel of 42 experts: 20 from the Korean Stroke Soci-
ety, 11 from the Korean Society of Interventional Neuroradi-
ology, and 11 from the Society of Korean Endovascular Neu-
rosurgeons. Using a 9-point scale modified from RAND Cor-
poration method, we asked experts to individually provide 
their ratings on individual recommendations: a score of 9 as 
strong agreement and a score of 1 as strong disagreement.39 
We defined scores 7-9 as agreement, 4-6 as uncertainty, and 
1-3 as disagreement. We considered that consensus on recom-
mendation was reached if 75% or more experts agreed. For 
recommendations with an agreement rate of less than 75% ex-
perts, additional Delphi rounds were conducted. 
Among 42 experts convened, 34 (81%) provided their rat-
ings, and the list of participants is provided in Supplemental 
Table 1. In the first Delphi round, consensus was achieved in 
18 recommendations, and the scores and agreement rates 
were generally high (Supplemental Table 2). In two recom-
mendations, the agreement rate was 68% and 71%, respec-
tively. Therefore, we revised the recommendations reflecting 
the opinion of respondents. In the second Delphi round, we 
achieved consensus with the agreement rate of 100% and 
96%. The final draft of the current guidelines was reviewed 
and approved by the participating academic societies.
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Recommendations
Recommendations for ERT, neuroimaging evaluation, and 
system organization are summarized in Table 3.
Estimation of ERT candidates in Korea
In Korea, about 75,000 ischemic strokes occur annually.40 
In a large prospective stroke registry enrolling 27,851 patients 
with acute ischemic strokes between April 2008 and Novem-
ber 2013, 4.6% were treated with ERT.41 However, the centers 
participated in the registry are likely to have a higher rate of 
ERT than an average rate in Korea. Data from a large hospital-
based registry of the USA showed that about 2.0% of patients 
with ischemic stroke received ERT in 2012.42 Accordingly, a 
reasonable projected rate of ERT in Korea would range from 
2.0% to 3.0%, indicating that currently 1,500-2,250 patients 
per year might receive ERT. However, according to a registry 
study in Korea, about 20% of patients had a severe stroke of 
baseline NIHSS score of ≥ 10,41 which were likely to be 
caused by large cerebral artery occlusion. Therefore, the num-
ber of patients who are indicated for ERT, if they arrive earlier, 
would be much greater. Patients with large cerebral artery oc-
clusion are usually severely disabled and dead without timely 
Table 3. Summary of recommendations
Recommendations References
Endovascular Recanalization Therapy (ERT)
   1.  In patients with major ischemic stroke due to an acute large artery occlusion in the anterior circulation (internal carotid artery, M1, 
   and possibly large M2 branch) within 6 hours, ERT is recommended to improve clinical outcomes (level of evidence [LOE] Ia, grade of 
   recommendation [GOR] A).
9-13,21
   2.  In patients eligible for intravenous tissue plasminogen activator (IV-TPA), administration of IV-TPA is recommended before the 
   initiation of ERT (LOE Ia, GOR A). Since IV-TPA should not significantly delay ERT, it is recommended to simultaneously proceed ERT 
   during IV-TPA treatment without waiting for clinical response to IV-TPA.
9-13,21
   3.  In patients who are contraindicated for IV-TPA, ERT is recommended as a first-line therapy in patients with major ischemic stroke due 
   to an acute large artery occlusion in the anterior circulation within 6 hours (LOE IIa, GOR B).
9-13
   4.  In patients with major ischemic stroke due to acute large artery occlusion in the poster circulation (basilar artery, P1, and vertebral 
   artery) within 6 hours, ERT can be considered (LOE III, GOR B).
31
   5.  For patients with acute large artery occlusion in the anterior or posterior circulation presenting after 6 hours, ERT can be considered 
   for patients having favorable multimodal imaging profiles regarding expected benefit and safety. Each center is encouraged to 
   define own selection criteria (LOE IV, GOR C).
10,13
   6. If indicated, ERT should be initiated as fast as possible (LOE IIa, GOR B). 37,38
   7. Stent-retriever thrombectomy is recommended as a first-line ERT (LOE Ia, GOR A). 9-13,21,29,30
   8.  If recanalization is not achieved with stent-retriever thrombectomy, the addition of other ERT modalities can be considered after taking 
   into account the expected efficacy and safety (LOE IV, GOR C).
9,10,21
   9.  Other mechanical thrombectomy or thrombus aspiration devices may be considered as a first-line modality at the discretion of 
   responsible interventionists after taking into account technical aspects (LOE IV, GOR C).
9,10,21
 10.  During ERT, conscious sedation is generally preferred to general anesthesia. However, the decision should be made after consideration  
   of patient’s condition and center’s experience (LOE III, GOR B).
33-36
Neuroimaging evaluation
   1. Noncontrast CT or MRI should be conducted to exclude hemorrhagic stroke or other non-stroke etiologies (good practice points [GPP]). 4,14-18,6-13,19
   2.  Non-invasive vascular imaging (CT angiography or MR angiography) is recommended to confirm acute large artery occlusion for 
   patients with major ischemic stroke (GPP).
9-13
   3.  For patients who are not able to perform non-invasive vascular imaging, stroke severity or clot sign on noncontrast CT can guide 
   decision for ERT (GPP).
24
   4. For selecting patients, neuroimaging evaluation for extensive early ischemic injury can guide decision for ERT (GPP). 9-13,28,29
   5.  Advanced multimodal imaging to assess collaterals, extent of ischemic core, or perfusion-diffusion mismatch can be considered to 
   identify patients who are likely to benefit from ERT (GPP). However, the multimodal imaging should not significantly delay ERT.
9-13
System organization
   1.  For centers capable of providing ERT, the organization and implementation of critical pathway and formal protocol are recommended to 
   accelerate the delivery of ERT (GPP).
10,12,22-24
   2.  For centers that are not adequately staffed for ERT, it is encouraged to have a referral plan to a center capable of ERT for patients 
    eligible for ERT. If indicated, initiating IV-TPA before referral is encouraged (GPP).
13,22-24,32
   3.  Each center is encouraged to define own criteria for the multidisciplinary ERT team that is responsible for initial evaluation, decision 
   making, and ERT procedure (GPP).
22-24
   4.  To assess and improve the quality of ERT, each center is encouraged to monitor key time metrics of door-to-neuroimaging and door-to- 
   groin puncture (GPP).
22-24
   5. It is encouraged to assess functional outcome, recanalization rate, and complication rate after ERT (GPP). 22-24
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reperfusion, and thereby we need to set up an organized stroke 
care system for ERT at regional or national level.
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Supplemental Table 2. Results of Delphi consensus
Recommendations
Delphi round 
achieving 
consensus
Agreement 
(score 7-9), 
(%)
Uncertainty 
(score 4-6), 
(%)
Disagreement 
(score 1-3), 
(%)
Endovascular Recanalization Therapy
  1. In patients with major ischemic stroke due to an acute large artery occlusion in the anterior 
        circulation (internal carotid artery, M1, and possibly large M2 branch) within 6 hours, 
        endovascular recanalization therapy (ERT) is recommended to improve clinical outcomes 
        (LOE Ia, GOR A).
First round 91.2 5.9 2.9
  2. In patients eligible for intravenous tissue plasminogen activator (IV-TPA), administration of 
        IV-TPA is recommended before the initiation of ERT (LOE Ia, GOR A). Since IV-TPA should not 
        significantly delay ERT, it is recommended to simultaneously proceed ERT during IV-TPA 
        treatment without waiting for clinical response to IV-TPA.
First round 94.1 2.9 2.9
  3. In patients who are contraindicated for IV-TPA, ERT is recommended as a first-line therapy 
        in patients with major ischemic stroke due to an acute large artery occlusion in the anterior 
        circulation within 6 hours (LOE IIa, GOR B).V
First round 97.1 2.9 0
  4. In patients with major ischemic stroke due to acute large artery occlusion in the poster 
        circulation (basilar artery, P1, and vertebral artery) within 6 hours, ERT can be considered 
        (LOE III, GOR B). 
First round 91.2 8.8 0
  5. For patients with acute large artery occlusion in the anterior or posterior circulation 
        presenting after 6 hours, ERT can be considered for patients having favorable multimodal 
        imaging profiles regarding expected benefit and safety. Each center is encouraged to define 
        own selection criteria (LOE IV, GOR C).
First round 88.2 8.8 2.9
  6. If indicated, ERT should be initiated as fast as possible (LOE IIa, GOR B). First round 91.2 5.9 2.9
  7. Stent-retriever thrombectomy is recommended as a first-line ERT (LOE Ia, GOR A). First round 76.5 20.6 2.9
  8. If recanalization is not achieved with stent-retriever thrombectomy, the addition of other 
        ERT modalities can be considered after taking into account the expected efficacy and safety 
        (LOE IV, GOR C).
First round 91.2 8.8 0
  9. Other mechanical thrombectomy or thrombus aspiration devices may be considered as a 
        first-line modality at the discretion of responsible interventionists after taking into account 
        technical aspects (LOE IV, GOR C).
First round 85.3 11.8 2.9
10. During ERT, conscious sedation is generally preferred to general anesthesia. However, the 
        decision should be made after consideration of patient’s condition and center’s experience 
        (LOE III, GOR B).
First round 91.2 8.8 0
Neuroimaging evaluation
  1. Noncontrast CT or MRI should be conducted to exclude hemorrhagic stroke or other 
        non-stroke etiologies (GPP).
First round 91.2 5.9 2.9
  2. Non-invasive vascular imaging (CT angiography or MR angiography) is recommended to 
        confirm acute large artery occlusion for patients with major ischemic stroke (GPP).
First round 91.2 5.9 2.9
  3. For patients who are not able to perform non-invasive vascular imaging, stroke severity or 
        clot sign on noncontrast CT can guide decision for ERT (GPP).
First round 91.2 5.9 2.9
  4. For selecting patients, neuroimaging evaluation for extensive early ischemic injury can 
        guide decision for ERT (GPP).
Second round 100 0 0
  5. Advanced multimodal imaging to assess collaterals, extent of ischemic core, or 
        perfusion-diffusion mismatch can be considered to identify patients who are likely to benefit 
        from ERT (GPP). However, the multimodal imaging should not significantly delay ERT.
First round 82.4 11.8 5.9
System organization
  1. For centers capable of providing ERT, the organization and implementation of critical 
        pathway and formal protocol is recommended to accelerate the delivery of ERT (GPP).
First round 91.2 8.8 0
  2. For centers which are not adequately staffed for ERT, it is encouraged to have a referral 
        plan to a center capable of ERT for patients eligible for ERT. If indicated, initiating IV-TPA 
        before referral is encouraged (GPP).
First round 88.2 11.8 0
  3. Each center is encouraged to define own criteria for the multidisciplinary ERT team that is 
        responsible for initial evaluation, decision making, and ERT procedure (GPP).
Second round 96 4 0
  4. To assess and improve the quality of ERT, each center is encouraged to monitor key time 
        metrics of door-to-neuroimaging and door-to-groin puncture (GPP).
First round 91.2 8.8 0
  5. It is encouraged to assess functional outcome, recanalization rate, and complication rate 
        after ERT (GPP).
First round 91.2 8.8 0
